{"entity":{"id":"nct07213804","kind":"trial","name":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer","aka":["FRAmework-01"],"tldr":"A phase 3 trial testing Sofetabart Mipitecan in ovarian cancer, now recruiting.","summary":"A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer is a phase 3 interventional study registered as NCT07213804, led by Eli Lilly and with GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT) and Asia-Pacific Gynecologic Oncology Trials, and recruiting on the registry. Official title: FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer. Planned enrolment is 1630 participants (estimated). The study started in 2025-10-22 and primary completion is expected in 2028-11. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07213804","url":"https://clinicaltrials.gov/study/NCT07213804"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["sofetabart-mipitecan"],"companies":["eli-lilly"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07213804","phase":"3","setting":"FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer","sponsor":"Eli Lilly and","started":"2025-10-22","startedType":"actual","enrolled":1630,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07213804/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"sofetabart-mipitecan","kind":"drug","name":"Sofetabart Mipitecan","route":"/drugs/sofetabart-mipitecan/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"}]}}